1,300 reports of this reaction
2.1% of all NICOTINE POLACRILEX reports
#6 most reported adverse reaction
DIZZINESS is the #6 most commonly reported adverse reaction for NICOTINE POLACRILEX, manufactured by Haleon US Holdings LLC. There are 1,300 FDA adverse event reports linking NICOTINE POLACRILEX to DIZZINESS. This represents approximately 2.1% of all 62,946 adverse event reports for this drug.
NICOTINE POLACRILEX has an overall safety score of 78 out of 100. Patients taking NICOTINE POLACRILEX who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for NICOTINE POLACRILEX, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for NICOTINE POLACRILEX:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 1,300 FDA reports for NICOTINE POLACRILEX. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.1% of all adverse event reports for NICOTINE POLACRILEX, making it a notable side effect.
If you experience dizziness while taking NICOTINE POLACRILEX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.